Risk Management Could Bolster FDA Behind-The-Counter Switches – Gottlieb
Executive Summary
FDA's authority to require behind-the-counter sale and other restrictions for some nonprescription switches is strengthened by risk management provisions of "FDA Revitalization" bills pending in Congress, according to former FDA Deputy Commissioner Scott Gottlieb
You may also be interested in...
BTC Class Might Not Happen Soon But FDA Working On Specific Proposal
Stakeholders in the concept of creating a behind-the-counter status for some drugs are at loggerheads on the need for a BTC class but agree on one point - FDA will need a long time to reach a decision on the issue
BTC Class Might Not Happen Soon But FDA Working On Specific Proposal
Stakeholders in the concept of creating a behind-the-counter status for some drugs are at loggerheads on the need for a BTC class but agree on one point - FDA will need a long time to reach a decision on the issue
Risk Management Only Part Of Behind-The-Counter Orders – Von Eschenbach
Enactment of legislation to strengthen FDA's post-marketing authority is not the only hurdle to clear before the agency could begin requiring "behind-the-counter" sales of certain nonprescription drugs, Commissioner Andrew von Eschenbach says